Strategies in the design of antiviral drugs

Nature Reviews Drug Discovery

Volumn 1, Issue 1, 2002, Pages 13-25

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 9 [1,2 BIS(HYDROXYMETHYL)CYCLOPROPYLMETHYL]GUANINE; ABACAVIR; ACICLOVIR; ADENOSYLHOMOCYSTEINASE INHIBITOR; ANTIVIRUS AGENT; DIDANOSINE; ENFUVIRTIDE; FAMCICLOVIR; GANCICLOVIR; GUANOSINE DERIVATIVE; INOSINATE DEHYDROGENASE INHIBITOR; LAMIVUDINE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NUCLEOSIDE ANALOG; PENCICLOVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIALIDASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VIRUS DNA; VIRUS RNA; ZALCITABINE; ZIDOVUDINE; ADENOSYLHOMOCYSTEINASE; ENZYME INHIBITOR; HYDROLASE; INOSINATE DEHYDROGENASE; SIALIDASE;

CLINICAL TRIAL; CYTOMEGALOVIRUS; DNA SYNTHESIS; DNA VIRUS; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EBOLA VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LICENCE; LIFE CYCLE; NONHUMAN; PARAMYXOVIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHINOVIRUS; RNA SYNTHESIS; VALIDATION PROCESS; VIRUS ADSORPTION; VIRUS CELL INTERACTION; VIRUS INFECTION; ADSORPTION; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; MEMBRANE FUSION;

ADENOSYLHOMOCYSTEINASE; ADSORPTION; ANIMALS; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG DESIGN; ENZYME INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; HYDROLASES; IMP DEHYDROGENASE; MEMBRANE FUSION; NEURAMINIDASE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 0036050539     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd703     Document Type: Review

References (94)

1. De Clercq, E. Antiviral drugs: current state of the art. J. Clin. Virol. 22, 73-89 (2001).
2. Gallaher, W. R., Ball, J. M., Garry, R. F., Martin-Amedee, A. M. & Montelaro, R. C. A general model for the surface glycoproteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses 11, 191-202 (1995).
3. Shukla, D. et al. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99, 13-22 (1999).
4. Chen, Y. et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nature Med. 3, 866-871 (1997).
5. Herold, B. C. et al. Poly(sodium 4-styrene sulfonate): an effective candidate topical antimicrobial for the prevention of sexually transmitted diseases. J. Infect. Dis. 181, 770-773 (2000).
6. Esté, J. A. et al. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol. Pharmacol. 52, 98-104 (1997).
7. Esté, J. A. et al. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (zintevir). Mol. Pharmacol. 53, 340-345 (1998).
8. Cabrera, C. et al. Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4. AIDS Res. Hum. Retroviruses 15, 1535-1543 (1999).
9. Schols, D. et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186, 1383-1388 (1997).
10. De Clercq, E. Inhibition of HIV Infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol. Pharmacol. 57, 833-839 (2000)
11. Baba, M. et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl Acad. Sci. USA 96, 5698-5703 (1999).
12. Dragic, T. et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl Acad. Sci. USA 97, 5639-5644 (2000).
13. Hatse, S. et al. Mutation of Asp171 and Asp262 of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol. Pharmacol. 60, 164-173 (2001).
14. Strizki, J. M. et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 12718-12723 (2001).
15. Root, M. J., Kay, M. S. & Kim, P. S. Protein design of an HIV-1 entry inhibitor. Science 291, 884-888 (2001).
16. Eckert, D. M., Malashkevich, V. N., Hong, L. H., Carr, P. A. & Kim, P. S. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99, 103-115 (1999).
17. Kilby, J. M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 4, 1302-1307 (1998).
18. Lambert, D. M. et al. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. Natl Acad. Sci. USA 93, 2186-2191 (1996).
19. Schwartz, J. A., Lium, E. K. & Silverstein, S. J. Herpes simplex virus type 1 entry is inhibited by the cobalt chelate complex CTC-96. J. Virol. 75, 4117-4128 (2001).
20. McGuigan, C. et al. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside apalogues with an unusual bicyclic base. J. Med. Chem. 42, 4479-4484 (1999).
21. McGuigan, C. et al. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J. Med. Chem. 43, 4993-4997 (2000).
22. Iwayama, S. et al. Antiherpesvirus activities of (1′S,2′R)-9-[[1′,2′-bis(hydroxymethyl -cycloprop-1′-yl]methyl] (A-5021) in cell culture. Antimicrob. Agents Chemother. 42, 1666-1670 (1998).
23. Ono, N. et al. Mode of action of (1′S,2′R)-9-[[1′,2′-bis(hydroxymethyl cycloprop-1′-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus. Antimicrob. Agents Chemother. 42, 2095-2102 (1998).
24. Wang, J. et al. The cyclohexene ring system as a furanose mimic synthesis arid antiviral activity of both enantiomers of cyclohexenylguanine. J. Med. Chem. 43, 736-745 (2000).
25. Siddiqui, A. Q. et al. Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture structural determinants for in vitro activity and QSAR. J. Med. Chem. 42, 4122-4128 (1999).
26. Saboulard, D. et al Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine. Mol. Pharmacol. 56, 693-704 (1999).
27. Meier, C., Lorey, M., De Clercq, E. & Balzarini, J. cycloSal-2′,3′-dideoxy-2′,3′-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system. J. Med. Chem. 41, 1417-1427 (1998).
28. Balzarini, J. et al. Cyclosaligenyl-2′,3′-didehydro-2′,3′-dideoxythymidine monophosphate: efficient intracellular delivery of d4TMP Mol. Pharmacol. 58, 928-935 (2000).
29. De Clercq, E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 38, 153-179 (1998).
30. Jonckheere, H., Anné, J. & De Clercq, E. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev. 20, 129-154 (2000).
31. Esnouf, R. M., Stuart, D. I., De Clercq, E., Schwartz, E. & Balzarini, J. Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives. Biochem. Biophys. Res. Commun. 234, 458-464 (1997).
32. Ren, J. et al. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J. Biol. Chem. 275, 14316-14320 (2000).
33. Pelemans, H., Esnouf, R., De Clercq, E. & Balzarini, J. Mutational analysis of Trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid reodue as a prime target for the rational design of new non-nucleoside RT inhibitors. Mol. Pharmacol. 57, 954-960 (2000).
34. Xiong, X., Smith, J. L. & Chen, M. S. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41, 594-599 (1997).
35. Balzarini, J., Hao, Z., Herdewijn, P., Johns, D G. & De Clercq, E. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl Acad. Sci. USA 88, 1499-1503 (1991).
36. De Clercq, E. et al. A novel selective broad-spectrum anti-DNA virus agent. Nature 323, 464-467 (1986).
37. De Clercq, E. Therapeutic potential of HPMPC as an antiviral drug. Rev. Med. Virol. 3, 85-96 (1993).
38. De Clercq, E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 14, 382-397 (2001).
39. Pommier, Y, Pilon, A. A., Bajaj, K., Mazumder, A. & Neamati, N. HIV-1 integrase as a target for antiviral drugs. Antiviral Chem. Chemother. 8, 463-483 (1997).
40. Pommier, Y., Marchand, C. & Neamati, N. Retroviral integrase inhibitors year 2000: update and perspectives. Antiviral Res. 47, 139-148 (2000).
41. Pluymers, W. et al. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol. Pharmacol. 58, 641-648 (2000).
42. Hazuda, D. J. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287, 646-650 (2000).
43. Wai, J. S. et al. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J. Med. Chem. 43, 4923-4926 (2000).
44. Daelemans, D., Vandamme, A.-M. & De Clercq, E. Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Antiviral Chem. Chemother. 10, 1-14 (1999).
45. Baba, M. et al. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol. Pharmacol. 53, 1097-1103 (1998).
46. Turpin, J. A. et al. Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrob. Agents Chemother. 42, 487-494 (1998).
47. Hamy, F. et al. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc. Natl Acad. Sci. USA 94, 3548-3553 (1997).
48. Daelemans, D. et al. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol. Pharmacol. 57, 116-124 (2000).
49. Chao, S. H. et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275, 28345-28348 (2000).
50. Dymock, B. W., Jones, P. S. &, Wilson, F. X. Novel approaches to the treatment of hepatitis C virus infection. Antiviral Chem. Chemother. 11, 79-96 (2000).
51. Paolini, C., De Francesco, R. & Gallinari, P. Enzymatic properties of hepatitis C virus NS3-associated helicase. J. Gen. Virol. 81, 1335-1345 (2000).
52. Carroll, S. S. et al. Only a small fraction of purified hepatitis C RNA-dependent RNA polymerase is catalytically competent: implications for viral replication and in vitro assays. Biochemistry 39, 8243-8249 (2000).
53. Patick, A. K. & Potts, K. E. Protease inhibitors as antiviral agents. Clin. Microbiol. Rev. 11, 614-627 (1998).
54. Erickson, J. W. & Burt, S. K. Structural mechanisms of HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 36, 545-571 (1996).
55. Turner, S. R. et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 41, 3467-3476 (1998).
56. Hagen, S. E. et al. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters. J. Med. Chem. 44, 2319-2332 (2001).
57. Waxman, L. & Darke, P. L. The herpesvirus proteases as targets for antiviral chemotherapy. Antiviral Chem. Chemother. 11, 1-22 (2000).
58. Jarvest, R. L. et al. Inhibition of herpes proteases and antiviral activity of 2-substituted thieno-[2,3-D]oxazinones. Bioorg. Med. Chem. Lett. 9, 443-448 (1999).
59. Smith, D. G. et al. The inhibition of human cytomegalovirus (hCMV) protease by hydroxylamine derivatives. Bioorg. Med. Chem. Lett. 9, 3137-3142 (1999).
60. Ogilvie, W. W. et al. Synthesis and antiviral activity of monobactams inhibiting the human cytomegalovirus protease. Bioorg. Med. Chem. 7, 1521-1531 (1999).
61. Borthwick, A. D. et al. Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus brotease. 1. The α-methyl-trans-lactam template. J. Med. Chem. 43, 4452-4464 (2000).
62. Matsumoto, M., Misawa, S., Chiba, N., Takaku, H. & Hayashi, H. Selective nonpeptidic inhibitors of herpes simplex virus type 1 and human cytomegalovirus proteases. Biol. Pharm. Bull. 24, 236-241 (2001).
63. Dragovich, P. S. et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J. Med. Chem. 41, 2806-2818 (1998).
64. Dragovich, P. S. et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. J. Med. Chem. 41, 2819-2834 (1998).
65. Dragovich, P. S. et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J. Med. Chem. 42, 1203-1212 (1999).
66. Dragovich, P. S. et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J. Med. Chem. 42, 1213-1224 (1999).
67. Matthews, D. A. et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl Acad. Sci. USA 96, 11000-11007 (1999).
68. Patick, A. K, et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 43, 2444-2450 (1999).
69. Tautz, N., Kaiser, A. & Thiel, H.-J. NS3 serine protease of bovine viral diarrhea virus: characterization of active site residues, NS4A cofactor domain, and protease-cofactor interactions. Virology 273, 351-363 (2000).
70. Llinàs-Brunet, M. et al. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Bioorg. Med. Chem. Lett. 10, 2267-2270 (2000).
71. Bennett, J. M. et al. The identification of α-ketoamides as potent inhibitors of hepatitis C virus NS3-4A proteinase. Bioorg. Med. Chem. Lett. 11, 355-357 (2001).
72. Sing, W. T., Lee, C. L., Yes, S. L., Lim, S. P. & Sim, M. M. Arylalkylidene rhodarine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor. Bioorg. Med. Chem. Lett. 11, 91-94 (2001).
73. Von Itzstein, M. et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 418-423 (1993).
74. Barnett, J. M. et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob. Agents Chemother. 44, 78-87 (2000).
75. Hayden, F. G. et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N. Engl. J. Med. 337, 874-880 (1997).
76. Kim, C. U. et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119, 681-690 (1997).
77. Mendel, D. B. et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42, 640-646 (1998).
78. Hayden, F. G. et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. J. Am. Med. Assoc. 282, 1240-1246 (1999).
79. Nicholson, K. G. et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355, 1845-1850 (2000).
80. Smee, D. F., Huffman, J. H., Morrison, A. C., Barnard, D. L. & Sidwell, R. W. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob. Agents Chemother. 45, 743-748 (2001).
81. Sidwell, R. W. et al. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201. Antimicrob. Agents Chemother. 45, 749-757 (2001).
82. Bantia, S. et al. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45, 1162-1167 (2001).
83. Sintchak, M. D. et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 85, 921-930 (1996).
84. De Clercq, E. et al. Antiviral activities of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob. Agents Chemother. 35, 679-684 (1991).
85. Markland, W., McQuaid, T. J., & Kwong, A. D. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with α-interferon. Antimicrob. Agents Chemother. 44, 859-866 (2000).
86. Neyts, J., Andrei, G. & De Clercq, E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob. Agents Chemother. 42, 216-222 (1998).
87. Margolis, D. et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J. Acquir. Immune Defic. Syndr. 21, 362-370 (1999).
88. Saracco, G. et al. A randomized 4-arm multicenter study of interferon-α-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 34, 133-138 (2001).
89. Crotty, S. et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nature Med. 6, 1375-1379 (2000).
90. Crotty, S., Cameron, C. E. & Andino, R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl Acad. Sci. USA 98, 6895-6900 (2001).
91. De Clercq, E. et al. Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5′-nor derivatives. Antimicrob. Agents Chemother. 33, 1291-1297 (1989).
92. Bray, M., Davis, K., Geisbert, T., Schmaljohn, C. & Huggins, J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 179 (Suppl. 1), S248-S258 (1999).
93. Huggins, J., Zhang, Z.-X. & Bray, M. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J. Infect. Dis. 179, (Suppl. 1) S240-S247 (1999).
94. Bray, M., Driscoll, J. & Huggins, J. W. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-D-homocysteine hydrolase inhibitor. Antiviral Res. 45, 135-147 (2000).